← Back to Search

Other

Implementation Strategies for Medication-Assisted Treatment for Opioid Addiction (SITT-MAT Trial)

N/A
Waitlist Available
Led By Mark McGovern, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Residential (detoxification or rehabilitation) or outpatient (intensive outpatient or outpatient) levels of care
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up months 1,7,14,24,34,46
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers understand how to best help addiction treatment programs implement new treatments, like medication-assisted treatment for opioid use disorder.

Who is the study for?
This trial is for addiction treatment programs in Washington State that handle opioid use disorder but are not opioid treatment programs. It includes residential detox or rehab, outpatient services, primary care clinics like FQHCs and CHCs.
What is being tested?
The study tests a stagewise approach to implementing medications for opioid use disorder (MOUD) across various addiction programs. Strategies include Enhanced Monitoring and Feedback, NIATx/MAT Academy, and randomization between two types of facilitation methods with goals of reaching specific implementation targets.
What are the potential side effects?
Since this trial focuses on the implementation strategies rather than direct patient interventions, it does not directly address medication side effects. However, MOUD can have side effects such as nausea, drowsiness, constipation which are not specifically studied here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am currently in a detox, rehab, or outpatient care program.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 1,7,14,24,34,46
This trial's timeline: 3 weeks for screening, Varies for treatment, and months 1,7,14,24,34,46 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adoption
Effectiveness
Implementation - Integrating Medications for Addiction Treatment (IMAT) Index
+1 more
Other study objectives
Contextual determinants
Cost of implementation
Engagement in implementation
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Group I: Path 5Experimental Treatment4 Interventions
Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation + NIATx External Facilitation
Group II: Path 4Experimental Treatment3 Interventions
Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation
Group III: Path 3Experimental Treatment3 Interventions
Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx External Facilitation
Group IV: Path 2Experimental Treatment2 Interventions
Enhanced Monitoring and Feedback + NIATx/MAT Academy
Group V: Path 1Experimental Treatment1 Intervention
Enhanced Monitoring and Feedback

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,472 Previous Clinical Trials
17,501,771 Total Patients Enrolled
1 Trials studying Opioid Addiction
422 Patients Enrolled for Opioid Addiction
University of Wisconsin, MadisonOTHER
1,230 Previous Clinical Trials
3,199,778 Total Patients Enrolled
Washington State Health Care AuthorityUNKNOWN

Media Library

Opioid Addiction Research Study Groups: Path 2, Path 3, Path 5, Path 4, Path 1
Enhanced Monitoring and Feedback (EMF) (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05343793 — N/A
~18 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top